Cloud-Clone antibody used in Cancer Cell study on HBV-linked liver cancer immunity

Researchers published in Cancer Cell a study of how PD-1 blockade can trigger HBV-specific B-cell responses in hepatocellular carcinoma, pointing to a possible new combination strategy for virus-associated liver cancer. The work used Cloud-Clone’s C3a antibody in complement-validation experiments and found anti-HBc antibodies may help suppress tumors through a C1q-dependent pathway.

Why it matters: - The study points to a second immune pathway for anti-PD-1 therapy beyond the usual T-cell model. - The findings suggest HBV-related liver cancer could respond to combination immunotherapy that pairs PD-1 blockade with anti-HBc antibody treatment. - The work also identifies a potential biomarker signal for predicting which patients may respond to immunotherapy.

What happened: - Cancer Cell published the research in July 2026 from Professor Kuang Ming’s team at The First Affiliated Hospital of Sun Yat-sen University. - The study examined 17 patients with resectable recurrent hepatocellular carcinoma enrolled in phase II trial NCT04615143. - The team used single-cell multi-omics, spatial transcriptomics, antibody cloning and animal models to study the tumor immune response after peri-operative anti-PD-1 treatment. - Researchers found two immune-response patterns among long-term recurrence-free survivors with late recurrence: a T-cell-dominant subtype and a B-cell-dominant subtype. - Cloud-Clone’s Complement Component 3a polyclonal antibody, Catalog No. PAA387Hu01, was used in complement-validation experiments.

The details: - B-cell-dominant tumors showed low T-cell expansion but strong enrichment of plasma cells and mature tertiary lymphoid structures. - The study says these tertiary lymphoid structures supported local B-cell activation and antibody affinity maturation inside the tumor. - HBcAg was detected in the cytoplasm, nucleus and extracellular space in HBV-associated hepatocellular carcinoma tissue. - Immunoelectron microscopy and immunohistochemistry showed higher HBcAg abundance in tumor tissue than in matched adjacent non-tumor liver tissue. - Spatial paired single-cell BCR sequencing found prominent somatic hypermutation in B-cell receptors inside tumor tertiary lymphoid structures. - The team’s spatial phylogenetic tree approach traced BCR clonal evolution in tissue samples. - The study reports that 84.3% of mutated BCR clones showed stronger HBcAg binding. - Recombinantly expressed high-affinity anti-HBcAg antibodies suppressed growth of HBcAg-positive liver tumors in animal models. - The anti-tumor effect disappeared when the antibodies were converted to a complement-incompetent IgG1 isotype or tested in C1q-knockout mice. - The antibodies also showed synergy with anti-PD-1 treatment in animal models. - Immunohistochemistry using Cloud-Clone’s C3a antibody detected C3a deposition in human hepatocellular carcinoma tissues. - The company’s C3a antibody is positioned for immunohistochemistry, Western blot and ELISA applications.

Between the lines: - The work challenges the idea that PD-1 blockade works mainly by activating effector T-cells. - The data support a model in which anti-PD-1 therapy can also stimulate local humoral immunity against HBV core antigen. - That shift matters for virus-associated cancers, where antiviral immune responses may be repurposed as anti-tumor tools. - The biomarker signal described in the study could help distinguish responders from non-responders if validated in larger cohorts.

What's next: - The research points to clinical testing of PD-1 and anti-HBc monoclonal antibody combinations in HBV-associated hepatocellular carcinoma. - Further validation will be needed before the HBV-related B-cell signature can be used as a response biomarker. - The study found no observed viral reactivation in animal-model combination therapy, but human confirmation will be important before translation.

The bottom line: - The Cancer Cell paper adds a new layer to checkpoint blockade biology and opens a potential treatment path for HBV-linked liver cancer that relies on anti-viral antibodies, not just T-cells. - More information is available in Cloud-Clone’s announcement.